Last reviewed · How we verify
NCT06117085
CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid Nodules
NA trial testing CellFX® Percutaneous Electrode (PE) System in Thyroid Nodule (Benign) in 30 participants. Completed in 18 November 2024.
18 November 2024
Quick facts
| Lead sponsor | Pulse Biosciences, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 13 April 2023 |
| Primary completion | 18 November 2024 |
| Estimated completion | 18 November 2024 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- CellFX® Percutaneous Electrode (PE) System
Conditions studied
- Thyroid Nodule (Benign) — all drugs for Thyroid Nodule (Benign) →
Sponsor
Pulse Biosciences, Inc.
Who can join
Adults 18 to 80, any sex, with Thyroid Nodule (Benign). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this clinical feasibility study is to evaluate initial clinical safety and device performance of the CellFX Percutaneous Electrode (PE) System for the treatment of symptomatic benign thyroid nodules.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
First-in-Human Clinical Feasibility Study of Ablation of Benign Thyroid Nodules Using Nanosecond Pulsed Field Ablation.
Spiezia S, Offi C, Misso C, Antonelli G, et al · · 2025 · PMID 40836795 · DOI 10.1177/10507256251372166
Verify or expand the search:
- PubMed search for NCT06117085
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thyroid Nodule (Benign)
Currently open trials in the same condition.
- NCT07255482 — Mortality Benefit of Ultrasound for Thyroid Nodules Identified With PET Imaging: Non-Inferiority Emulated Target Trial · active not recruiting
- NCT06729762 — Ultrasound-guided Thermal Ablation for Benign Thyroid Nodules · recruiting
- NCT06779747 — Evaluation of Different Diagnostic Therapeutic Strategies in Patients with Thyroid Pathology · recruiting
- NCT04666103 — Function Integrity of Neck Anatomy in Thyroid Surgery · NA · recruiting
Other Pulse Biosciences, Inc. trials
Trials by the same sponsor.
- NCT07287176 — Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System · NA · recruiting
- NCT06355063 — CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation · NA · recruiting
- NCT06696170 — CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial Fibrillation · NA · recruiting
- NCT04918381 — CellFX Treat & Resect Low-Risk BCC Feasibility Study · NA · completed
- NCT04738734 — CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06117085 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pulse Biosciences, Inc.
- Last refreshed: 21 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06117085.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing